HD-OPM Archive
Topics › PCSK9, ezetimibe & newer drugs

Obicetrapib gets first approval worldwide in the EU, lowering LDL up to 40-50%

Louis Nervegna · Sep 21, 2026 · ♥ 18 reactions · 5 comments · original Facebook post
PCSK9, ezetimibe & newer drugsLDL, ApoB & lipid panelBrain health & dementia
AI summary & key facts

The European Commission approved obicetrapib, a low-dose oral CETP inhibitor, on 21 September 2026 in two versions: obicetrapib 10 mg alone and combined with ezetimibe 10 mg. Phase 3 trials reported LDL-C reductions of about 40% alone and about 50% with ezetimibe versus placebo. The poster says the drug has shown promise for both cardiovascular disease and Alzheimer's.

This drug has shown promise in preventing both CVD and Alzheimer’s.

Quoted:

“Some very exciting news for those of us who have been following obicetrapib, the new oral CETP inhibitor developed by NewAmsterdam Pharma.

Today, September 21, 2026, the European Commission granted marketing authorization for obicetrapib, marking its first regulatory approval anywhere in the world.

Two versions have been approved:

Ubeslo® — obicetrapib 10 mg as a once-daily tablet.

Evlarco® — a single tablet combining obicetrapib 10 mg with ezetimibe 10 mg.

This is particularly interesting because obicetrapib has produced substantial LDL-C reductions in Phase 3 trials. NewAmsterdam reports reductions of up to approximately 40% with obicetrapib alone and approximately 50% when combined with ezetimibe, compared with placebo. Tolerability in these trials was reported as comparable to placebo.

Obicetrapib is a CETP inhibitor, but unlike earlier drugs in this class, it is a low-dose oral therapy being developed primarily for its ability to substantially lower LDL-C and other atherogenic lipoproteins.

For those of us interested in APOE4 and cardiovascular risk reduction, this is a development worth watching closely. Cardiovascular health and brain health are intimately connected, although it is important to emphasize that obicetrapib is not approved as an Alzheimer’s treatment or prevention therapy.”

#obicetrapibHD #apoe4HD #cetpinhibitorHD #alzheimersHD #hdlHD #dementiaHD #ldlHD

apoe44.orgObicetrapib Just Received European ApprovalSome very exciting news for those of us who have been following obicetrapib, the new oral CETP inhibitor developed by NewAmsterdam Pharma.apoe44.org

Research cited

← newer: Video analysis: keto beat Mediterranean and low-fat plant-baolder: Oatmeal eaters had 21% lower coronary heart disease risk in →